MetaCurUm Biotech develops a new treatment of aggressive cancer. The company is a spin-off from Umeå University and was founded by Professor Maréne Landström. MetaCurUm Biotech is a resident at Umeå Biotech Incubator.
The company has now been named one of two winners of an innovation competition and will receive a prize consisting of an IPR consultation worth SEK 75,000. The competition was announced by Groth & Co in conjunction with their 150th anniversary, where Swedish innovation companies were invited to compete for a price worth SEK 150,000. Among many impressive and innovative companies, the jury was able to agree on two worthy winners, MetaCurUm Biotech and Mycorena, who will split the prize money and thus receive counseling for SEK 75,000 each.
”Cancer is the most common cause of death in Sweden for people younger than 80 years. Therefore, we would like to contribute to MetCurUm Biotech’s development. I would be very happy and proud if we have helped them succeed in developing a treatment that can improve the quality of life and extend the survival of cancer patients,” says Mats Lundberg, CEO of Groth & Co.
MetaCurUm Biotech’s main focus is on prostate cancer, which is the most common form of cancer among men in Sweden, but there are indications that the treatment may also be relevant in other types of cancer.
”Our long term goal is to provide patients suffering from aggressive cancer with a new treatment option. We are currently working on showing that the treatment works in a cancer model. At the same time, we aim to raise money so that we can finance our continued development,” says Lotta Berg.
”To receive a consultation worth SEK 75,000 really makes a difference in the phase that the company is in right now, and it is a very valuable help to receive.”
The other winner of the competition, Mycorena, transforms residues from the food industry into an edible, sustainable and vegan fungal protein.
About MetaCurUm Biotech
MetCurUm Biotech is a spin-off company from Umeå University that is developing a new treatment strategy for aggressive cancer.
For more information, please contact:
Lotta Berg, CEO of MetaCurUm Biotech AB
+ 46 70-190 77 12
Viktor Backemar, Marketing Manager at Groth & Co
+46 70-299 91 38